N/A N=38 Gait Modification Treatments for Knee Pathology
Knee Injuries · Knee Osteoarthritis
Primary: Change in Peak Knee Flexion Moment (%Bw*Ht) — 0.197; 0.018 %Bw*Ht — p=0.005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
Phase 4 N=4,372 Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC) — 1.13; 1.13; 1.13; 0.77 participants with event/100 PY
N/A N=820 Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Chronic Myeloid Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on National Cancer Institute Common Terminology Criteria for…
Phase 1 N=17 A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Relapsed or Refractory Neuroblastoma
Primary: To Evaluate the Feasibility of 1RG-CART Therapy in Patients With Relapsed or Refractory Neuroblastoma — 0; 0; 0; 0 Participants
N/A N=1,121 Evaluation of the Antimicrobial Effectiveness of CHG/IPA
Microbial Colonization
Primary: Antimicrobial log10 Reductions From Baseline for Investigational Product and Reference Standard at 30 Seconds and 6 Hours Post-product Application — 2.53; 2.70; 2.68…
N/A N=120 Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Time Spent in Blood Glucose Range (70-180mg/dL) — 64.99; 62.54 percentage of time — p=0.64
N/A N=41 Effects of Lifestyle Modification on Vestibular Migraine
Vestibular Migraine
Primary: Headache Disability Inventory (HDI) — 14.3 score on a scale — p=<.0001
N/A N=32 Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke
Stroke · Balance; Distorted
Primary: Difference in Berg Balance Scale Pre-intervention and Post-intervention Assessment Scores — 30.20; 45.27; 30.43; 48.29 Score on a Scale — p=<0.0001
Phase 3 N=104 Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer
Rectal Cancer
Primary: 30-day Uncomplicated Perineal Wound Healing — 30; 33 Participants
Phase 2 N=136 Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Type 1 Diabetes Mellitus · New-onset Type 1 Diabetes Mellitus · T1DM
Primary: Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants — -0.337; -0.391 pmol/mL — p=0.277
Phase 1 N=29 A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Pediatric Solid Tumor · Refractory Tumor · Recurrent Tumor
Primary: Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab — 1; 1 Participants
Phase 2 N=74 Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Potentially Clinically Significant Hematology Results — 5; 2; 3; 4 Participants
Phase 3 N=162 Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
Chronic Severe Plaque-type Psoriasis
Primary: Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12 — 32; 31; 6; 26 Participants — p=<.0001
N/A N=45 Tantrum Tamers 2.0: The Role of Emotion
Child Behavior · Attention Deficit and Disruptive Behavior Disorders · Problem Behavior
Primary: Change in Eyberg Child Behavior Inventory (ECBI) Score-Intensity — -45.46 score on a scale